Episode 319 -- Deep Dive into SCG Plastics' $20 Million Settlement with OFAC for Violations of the Iran Sanctions Program
Joint Venture Basics for Large and Small Contractors
Bidding for Major Contracts? Compliance Requirements You Should Prepare for Now
Marriages don't last forever: How to terminate a Joint Venture - and come out of it relatively unscathed. Podcast episode 2
Marriages don't last forever - When Joint Ventures go wrong. Podcast episode 1
Construction Webinar Series: Building Compliance: Construction Industry Concerns Under FCA
Ashley Coselli and Daniel Wendt on Difficult Anti-Corruption Due Diligence Projects
Teeming with Teaming Agreements: Navigating Strategic Alliances in the Federal Marketplace
CIO-SP4 Is Ready To Launch: Is Your Business Equipped to Compete?
Roadmap to Joint Venture Agreements: Legal and Accounting Considerations
M&A Webinar - Trendspotting: The Rise of the Atypical Deal
SBA’s Final Rule on SBA’s MP Program, Joint Ventures, Affiliation and 8(a) Regulations
SBA’s Final Rule on Mentor-Protégé Programs: Key Changes for Government Contractors
Growth Strategies for Small Businesses Moving to Mid-Tier
Litigating During COVID: What You Need to Know
Shoot for the STARS: Q&A with SBA’s John Klein on GSA's 8(a) STARS III RFP
Williams Mullen's COVID-19 Comeback Plan: Selling Products and Services to the Federal Government
Day 18 of One Month to More Effective Compliance for Business Ventures-Financial Review of Your Business Venture Partner
Day 15 of One Month to More Effective Compliance for Business Ventures- Tying It All Together for Joint Ventures
Day 14 of One Month to More Effective Compliance for Business Ventures-Auditing Joint Ventures
Teva and Celltrion Healthcare announced today the U.S. launch of TRUXIMA® (rituximab-abbs) for rheumatoid arthritis (RA). TRUXIMA®, which originally launched in November 2019, is now approved to treat RA, non-Hodgkin lymphoma...more
On September 20, Teva Pharmaceutical Industries Ltd. and Regeneron Pharmaceuticals, Inc. announced an agreement to develop and commercialize fasinumab, an investigational NGF antibody currently under development by Regeneron...more